Articles tagged "Immunosuppression"

2015 American Transplant Congress
Kidney Transplant Function After Late Conversion to Belatacept (Nulojix®)
S. Brakemeier,¹ M. Dürr,¹ M. Wiesener,² B. Tobias,² K. Budde,¹ B. Klemens.¹
¹Nephrology, Charite Campus Mitte, Berlin, Germany; ²Nephrology, University Erlangen-Nuremberg, Erlangen, Germany.
Introduction: In the long-term follow up of kidney transplants, chronic transplant nephropathy often in combination with CNI-toxicity is a major problem. With declining transplant function…
2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
O. Rissling, P. Glander, P. Hambach, M. Mai, S. Brakemeier, D. Klonower, F. Halleck, E. Singer, E. Schrezenmeier, M. Duerr, H. Neumayer, K. Budde.
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…
2015 American Transplant Congress
Patient Self-Reported Adherence to and Perceptions Towards Immunosuppressive Medications at the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH)
K. Kak,¹ C. Burger,¹ D. Treleaven,² C. Wallace.¹
¹Pharmacy, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada; ²Medicine, McMaster University, Hamilton, ON, Canada.
Objectives To gain insight into the immunosuppressant adherence of patients followed by the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH) and to…
2015 American Transplant Congress
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
R. Hotta,¹ M. Ohira,² T. Matsuura,¹ I. Muraoka,¹ P. Tryphonopoulos,¹ J. Fan,¹ A. Tekin,¹ H. Ohdan,² A. Tzakis,³ R. Vianna,¹ S. Nishida.¹
¹University of Miami, Miami, FL; ²Hiroshima University, Hiroshima, Japan; ³Cleveland Clinic Florida, Weston, FL.
Background: T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface…
2015 American Transplant Congress
Prospective Study of a Steroid Free, Low Dose Tacrolimus and Everolimus Combination Regimen in Kidney Transplant
A. Shetty,¹ J. Leventhal,¹ O. Traitanon,¹ A. Alvarado,¹ V. Mas,² J. Mathew,¹ E. Tantisattamo,¹ L. Gallon.¹
¹Nephrology/Comprehensive Transplant, Northwestern University, Chicago; ²Surgery, Virginia Commonwealth University, Richmond.
Calcineurin(CNI) based therapy is the cornerstone of immunosuppresion(IS) after kidney transplant. However chronic nephrotoxicity from CNI as been implicated in post-transplant renal dysfunction. We hypothesized…
2015 American Transplant Congress
Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias
V. Domínguez-Pimentel,¹ F. Fortich-Barrios,¹ O. Siverio-Morales,¹ E. Martín-Izquierdo,¹ A. Jarque-López,¹ N. Del Castillo-Rodríguez,¹ J. García,¹ P. Ríos,² M. Macía.¹
¹Division of Nephrology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain; ²Division of Hematology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
INTRODUCTION:The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic…
2015 American Transplant Congress
Post-Kidney Transplant Infections in Desensitized Patients Receiving Thymoglobulin or Daclizumab Induction: Results of a Randomized Clinical Trial
B. Orandi,¹ J. Locke,² E. Kraus,³ B. Lonze,¹ N. Desai,¹ N. Dagher,¹ N. Alachkar,³ C. Simpkins,⁴ F. Naqvi,³ D. Segev,¹ R. Montgomery,¹ R. Avery.³
¹Department of Surgery, Johns Hopkins University, Baltimore; ²Department of Surgery, University of Alabama--Birmingham, Birmingham; ³Department of Medicine, Johns Hopkins University, Baltimore; ⁴Department of Surgery, Dartmouth, Lebanon.
Live donor kidney transplant recipients requiring desensitization for donor-specific antibody, who were enrolled in a single-center randomized trial of thymoglobulin vs. daclizumab induction, were evaluated…
2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
R. Bray,¹ H. Gebel,¹ R. Townsend,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta; ²Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…
2015 American Transplant Congress
Impact of Human Mutant TGF-β1/Fc Protein On Memory and Regulatory CD4+T Cells Following Lymphodepletion in Rhesus Monkeys
H. Guo,¹ L. Lu,¹ R. Wang,² H. Abdulkerim,² R. Keith,² A. Thomson,¹ M. Ezzelarab.¹
¹Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²MassBiologics, University of Massachusetts Medical School, Boston, MA.
Background:Tolerance to allografts is essential to avoid chronic immunosuppression and to promote long term graft function. Transforming growth factor- β plays a key role in…
2015 American Transplant Congress
Effect of Everolimus on Cardiovascular Parameters in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
H. Holdaas,¹ M. van der Giet,¹ J. de Fijter,¹ A. Speziale,² C. Escrig,² G. Junge,² Z. Wang,³ J. Cruzado.¹
¹For the ELEVATE Study, Oslo, Norway; ²Novartis, Basel, Switzerland; ³Novartis Corporation, East Hanover, NJ.
Background: Long-term exposure to calcineurin inhibitors (CNIs) contributes to an unfavorable cardiovascular (CV) risk profile, including inferior renal allograft function and premature graft loss with…